Cohance Lifesciences · NSE: COHANCE · BSE: 543064
Q1 FY25 results · Apr–Jun 2024
Cohance Lifesciences reported revenue from operations of ₹230.69 crore (down 33.6% from Q1 FY24) and net profit of ₹60.76 crore (down 49.6% from Q1 FY24) for Q1 FY25 (Apr–Jun 2024), on a consolidated basis.
| Item | Q1 FY25 | Q1 FY24 | YoY | Q4 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 230.69 | 347.55 | −33.6% | 252.93 | −8.8% |
| Other income | 18.16 | 10.67 | +70.2% | 17.05 | +6.5% |
| Total income | 248.85 | 358.22 | −30.5% | 269.98 | −7.8% |
| Profit before tax | 83.08 | 163.94 | −49.3% | 70.85 | +17.3% |
| Net profit for the period | 60.76 | 120.59 | −49.6% | 53.37 | +13.8% |
| EPS, basic (₹) | 2.39 | 4.74 | not comparable | 2.10 | not comparable |
| Net margin (%) | 26.3 | 34.7 | 21.1 |
| Item | Q1 FY25 | Q1 FY24 | YoY | Q4 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 222.09 | 344.03 | −35.4% | 243.52 | −8.8% |
| Other income | 17.95 | 10.06 | +78.5% | 16.87 | +6.5% |
| Total income | 240.04 | 354.08 | −32.2% | 260.39 | −7.8% |
| Profit before tax | 87.39 | 167.65 | −47.9% | 71.06 | +23.0% |
| Net profit for the period | 65.08 | 124.29 | −47.6% | 53.43 | +21.8% |
| EPS, basic (₹) | 2.56 | 4.88 | not comparable | 2.10 | not comparable |
| Net margin (%) | 29.3 | 36.1 | 21.9 |
Consolidated
- Filed with BSE
- 13 Aug 2024, 12:59 IST
- Board meeting
- 09 Aug 2024
- Period
- 01 Apr 2024 to 30 Jun 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 13 Aug 2024, 12:59 IST
- Board meeting
- 09 Aug 2024
- Period
- 01 Apr 2024 to 30 Jun 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE